Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLD: Bevacizumab, Olaparib, and Durvalumab in Relapsed Ovarian Cancer
NCT04015739Phase 2Unknown
- Sponsor
- ARCAGY
- Start
- Mar 2019
- Primary completion
- Jun 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by ARCAGY. Status: unknown.
02
Drugs
durvalumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04015739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04015739.